ScholarMate
客服热线:400-1616-289

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Muhammad, Shan; Fan, Tao; Hai, Yang; Gao, Yibo*; He, Jie*
Science Citation Index Expanded
哈尔滨医科大学; 中国医学科学院; 中国医学科学院北京协和医院

摘要

Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function and expression in the tumor microenvironment make them attractive targets for immunotherapy, leading to the development of IL-2/IL-2R-targeted therapeutic strategies. However, the dynamic interplay between IL-2/IL-2R and various immune cells and their dual roles in promoting immune activation and tolerance presents a complex landscape for clinical exploitation. This review discusses the pivotal roles of IL-2 and IL-2R in tumorigenesis, shedding light on their potential as diagnostic and prognostic markers and their therapeutic manipulation in cancer. It underlines the necessity to balance the anti-tumor activity with regulatory T-cell expansion and evaluates strategies such as dose optimization and selective targeting for enhanced therapeutic effectiveness. The article explores recent advancements in the field, including developing genetically engineered IL-2 variants, combining IL-2/IL-2R-targeted therapies with other cancer treatments, and the potential benefits of a multidimensional approach integrating molecular profiling, immunological analyses, and clinical data. The review concludes that a deeper understanding of IL-2/IL-2R interactions within the tumor microenvironment is crucial for realizing the full potential of IL-2-based therapies, heralding the promise of improved outcomes for cancer patients.

关键词

Interleukin-2 (IL-2) IL-2 receptor (IL-2R) Tumor microenvironment IL-2-based immunotherapy Regulatory T cells Cancer biomarkers Engineered IL-2 variants Combination cancer therapy Checkpoint inhibitors Tumor immune response Dose optimization of IL-2 Cancer prognosis and IL-2 Immune activation and tolerance Tumorigenesis Personalized cancer treatment Cancer immunosurveillance